Letter to the Editor
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Dec 15, 2024; 16(12): 4757-4761
Published online Dec 15, 2024. doi: 10.4251/wjgo.v16.i12.4757
Advancing hepatocellular carcinoma treatment with hepatic arterial infusion chemotherapy
Eda Caliskan Yildirim, Yakup Ergun
Eda Caliskan Yildirim, Department of Medical Oncology, Sincan Training and Research Hospital, Ankara 06100, Türkiye
Yakup Ergun, Department of Medical Oncology, Bower Hospital, Diyarbakır 21100, Türkiye
Author contributions: Caliskan Yildirim E reviewed the literature and wrote the manuscript; Ergun Y contributed to the discussion and design of the manuscript; All authors reviewed, edited, and approved the final manuscript and revised it critically for important intellectual content, gave final approval of the version to be published and agreed to be accountable for all aspects of the work.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yakup Ergun, MD, Associate Professor, Department of Medical Oncology, Bower Hospital, Yenisehir, Elazıg Street, Diyarbakır 21100, Türkiye. dr.yakupergun@gmail.com
Received: July 19, 2024
Revised: October 9, 2024
Accepted: October 18, 2024
Published online: December 15, 2024
Processing time: 116 Days and 2.5 Hours
Core Tip

Core Tip: Hepatic arterial infusion chemotherapy (HAIC) is shown to be a highly effective and safer treatment for advanced hepatocellular carcinoma. Despite its success in Asia, HAIC is underutilized in western countries. Further research and clinical trials in diverse populations are essential to validate HAIC’s benefits and integrate it into global oncology practices.